Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer

Tong Li¹, Rui Song², Jingjie Wang¹, Jianbo Zhang¹, Hongxing Cai¹, Hongmei He¹, Wei Hu¹, Dajun Yu³, Chuanhu Wang³, Qingbo Pan², Mingli Peng², Hong Ren²,⁎, Peng Zhu¹,⁎

¹ Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
² Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
³ Department of General Surgery, The Remin Hospital of Wushan country, Chongqing, China

ARTICLE INFO

Article history:
Received 5 July 2022
Revised 18 July 2022
Accepted 21 July 2022

Keywords:
COVID-19
Inactivated vaccine
Memory B cells

ABSTRACT

Objectives: This study aimed to evaluate the safety and immunogenicity of inactivated COVID-19 vaccines in patients with gastrointestinal cancer (GI) cancer. The role of memory B cells (MBCs) in the humoral response to COVID-19 vaccination was also investigated.

Methods: In this prospective observational study, GI cancer patients and healthy individuals who had received 2 doses of inactivated COVID-19 vaccines were included. The data regarding adverse effects, serum anti-receptor binding domain (RBD)-IgG, neutralizing antibodies (NAbs), and frequencies of MBCs were collected prospectively.

Results: The inactivated COVID-19 vaccines were safe and well tolerated. Serum anti-RBG-IgG and NAbs were lower for cancer patients. Old age, high ASA score, and receiving active chemotherapy were risk factors for lower antibody titers. The frequencies of activated and resting MBCs decreased in (17.45% vs 38.11%, P = 0.002; 16.98% vs 34.13%, P = 0.023), while the frequencies of intermediate and atypical MBCs increased in cancer patients (40.06% vs 19.87%, P = 0.010; 25.47% vs 16.61%, P = 0.025). The serum antibody titer decreased gradually during follow-up but increased when a booster vaccine was given.

Conclusion: The inactivated COVID-19 vaccines were well tolerated in patients with GI cancer but with lower immunogenicity. The subpopulations of MBCs were dosed in cancer patients, and a booster vaccine may be prioritized for them.

© 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

The COVID-19 pandemic has spread worldwide, with over 500 million confirmed cases and over 6 million deaths as of July 2022. It is the most unprecedented public crisis in nearly two hundred years (Kudhail et al., 2022; Lyudovyk et al., 2022; Ntagereka et al., 2022).

Cancer patients are at a higher risk of acquiring COVID-19 due to immunosuppression and a higher explosion rate with frequent hospital visits (Cortés et al., 2022). Javadinia (Javadinia et al., 2022a) reported that almost 20% of cancer patients might suffer from asymptomatic COVID-19. Moreover, cancer patients were reported to have a higher rate of COVID-19-induced mortality and the need for mechanical ventilation (Shahidsales et al., 2021; Taghizadeh-Hesary et al., 2021). Vaccination is the most convenient and economical way to decrease the impact of COVID-19 (Mattiuizi and Lippi, 2022). However, COVID-19 vaccines might be less effective for cancer patients, older patients, those suffering from hematologic malignancies, or those receiving chemotherapies (Ariamanesh et al., 2022; Javadinia et al., 2022b);
However, the opposite results also exist. The vaccination against COVID in cancer trial showed non-inferiority of two mRNA vaccines in patients receiving immunotherapy, chemotherapy, or chemoimmunotherapy for solid tumors compared with healthy individuals (Oosting et al., 2021). The role of COVID-19 vaccination remains a challenging issue, and minimal data exist on the safety and immunogenicity of inactivated COVID-19 vaccines.

Memory B cells (MBCs) play an essential role in the humoral response to vaccination. When the first dose of vaccine is administered, the receptor binding domain (RBD)-specific MBCs are generated that differentiate into antibody-secreting plasma cells upon administration of the second dose (Oliveiro et al., 2020). Our previous study found that a decrease in the frequency of RBD-specific MBCs in immunocompromised patients might lead to a lower seroprevalence of anti-RBD-IgG (Ao et al., 2022). However, the frequency of MBCs and their correlation with antibody titer have not been thoroughly studied in cancer patients.

In this study, we recruited 157 GI cancer patients and 117 healthy controls to study the safety and immunogenicity of inactivated COVID-19 vaccines. The response of MBCs and their four subpopulations was also detected.

Methods

Participants and study design

Patients diagnosed with GI cancer, mainly gastric cancer, colorectal cancer, and liver cancer (including patients with metastatic diseases) in the Second Affiliated Hospital of Chongqing Medical University and healthy controls from the health management center of the same hospital were recruited consecutively between October 2021 and March 2022 (approximately 800,000 people were infected with COVID-19 in China during the time of the study). The inclusion criteria were as follows: (i) 7-120 days after complete vaccination (BBIBP-CorV/Corona VAC/CHO, all inactivated COVID-19 vaccines).

Table 1

| Variables                              | GI cancer patients (n = 157) | Healthy controls (n = 117) | P-value |
|----------------------------------------|------------------------------|----------------------------|---------|
| Age (years)                            | 47.4 (32.79)                 | 53.5 (44.61)               | 0.727   |
| Gender, male, n (%)                    | 106 (67.32)                  | 78 (66.67)                 | 0.882   |
| Days after 2nd dose vaccination (days) | 47.4 (32.79)                 | 54.5 (34.75)               | 0.706   |
| BMI                                    | 22.00 (20.70-24.49)          | 22.86 (21.22-25.39)        | 0.209   |
| Vaccine type                           |                              |                            |         |
| BBIBP-CorV, n (%)                      | 50 (31.85)                   | 43 (36.75)                 |         |
| CoronaVac, n (%)                       | 81 (51.59)                   | 51 (43.59)                 | 0.831   |
| Mixed vaccination, n (%)               | 2 (1.27)                     | 6 (5.13)                   |         |
| Zhifei Longcom, China, n (%)           | 24 (12.74)                   | 17 (14.53)                 |         |
| Cancer type                            |                              |                            |         |
| Gastric cancer, n (%)                  | 15 (9.55)                    | /                          |         |
| Liver cancer, n (%)                    | 78 (49.68)                   | /                          |         |
| Intestinal cancer, n (%)               | 64 (40.76)                   | /                          |         |
| Anticancer therapy                     |                              |                            |         |
| Active treatment†, n (%)               | 107 (68.15)                  | /                          |         |
| Previous treatment, n (%)              | 28 (17.83)                   | /                          |         |
| Treatment naive, n (%)                 | 22 (14.02)                   | /                          |         |
| Therapy type (active)                  |                              |                            |         |
| Chemotherapy naive, n (%)              | 52 (48.60)                   | /                          |         |
| Chemotherapy (other therapy(ies)), n (%)| 55 (51.40)                   | /                          |         |

BMI = body mass index; GI = gastrointestinal.

† Patients undergoing anticancer therapy within 6 months before the first dose vaccination.
Figure 2. Antibody responses to inactivated SARS-COV-2 vaccines in patients with gastrointestinal cancer and healthy controls. The titers and seropositivity rate of anti-RBD-IgG (a-b) and NAbs (c-d) in cancer patients and healthy controls. The anti-RBD-IgG (e) and NAbs (f) titers are presented according to different numbers of days post vaccination. The trendlines were generated using a single linear model fit, and the shaded area represents the confidence interval for each fit with a 95% level of confidence. The correlation between the two antibodies (g) The horizontal dotted lines represent the limit of detection. The error bars represent the median (IQR). * P < 0.05, ** P < 0.01.

IQR = interquartile range; Nabs = neutralizing antibodies; RBD = receptor binding domain.

| AES WITHIN 7 DAYS | GI CANCER PATIENTS (N = 157) | HEALTHY CONTROLS (N = 117) | P-VALUE |
|-------------------|-------------------------------|----------------------------|---------|
| OVERALL AES       | 35, (22.29%)                  | 20, (17.09%)               | 0.288   |
| LOCAL AES         |                               |                            |         |
| PAIN              | 31, (19.75%)                  | 24, (20.52%)               | 0.875   |
| SWELLING          | 5, (3.18%)                    | 2, (1.71%)                 | 0.705   |
| REDNESS           | 0                             | 0                          | -       |
| ITCH              | 6, (3.82%)                    | 0                          | 0.085   |
| INDURATION        | 0                             | 0                          | -       |
| SYSTEMIC AES      |                               |                            |         |
| MUSCLE PAIN       | 8, (5.10%)                    | 2, (1.71%)                 | 0.249   |
| PRURITUS          | 1, (0.64%)                    | 0                          | 1.000   |
| RASH              | 1, (0.64%)                    | 0                          | 1.000   |
| FATIGUE           | 16, (10.20%)                  | 4, (3.42%)                 | 0.249   |
| DROWSINESS        | 1, (0.64%)                    | 2, (1.71%)                 | 0.797   |
| DIZZINESS         | 5, (3.18%)                    | 0                          | 0.136   |
| HEADACHE          | 5, (3.18%)                    | 0                          | 0.136   |
| RHINORRHEA        | 0                             | 0                          | -       |
| LARYNGEAL PAIN    | 0                             | 0                          | -       |
| FEVER             | 0                             | 0                          | -       |
| CHILL             | 0                             | 0                          | -       |
| COUGH             | 0                             | 0                          | -       |
| INAPPETENCE       | 5, (3.18%)                    | 0                          | 0.136   |
| ABDOMINAL PAIN    | 4, (2.54%)                    | 0                          | 0.219   |
| ABDOMINAL DISTENSION | 4, (2.54%)        | 0                          | 0.219   |
| DIARRHEA          | 1, (0.64%)                    | 0                          | 1.000   |
| HEPATALGIA        | 2, (1.27%)                    | 0                          | 0.509   |
| NAUSEA            | 3, (1.91%)                    | 0                          | 0.359   |
| CHEST DISTRESS    | 1, (0.64%)                    | 0                          | 1.000   |
| CONSTIPATION      | 0                             | 0                          | -       |

AE = adverse event; GI = gastrointestinal
19 vaccines produced in China) and (ii) age >18 years. Individuals with the following conditions were excluded: (i) history of COVID-19 infection, (ii) pregnancy, and (iii) autoimmune diseases.

The minimum sample size for the evaluation of COVID-19 vaccine effectiveness using the WHO sample size calculator was estimated to be 172 people (https://apps.who.int/iris/handle/10665/340303). We set the predicted vaccine effectiveness to 90%, the desired precision width to 20%, and the attack rate to 30%, according to previous studies (Joudi et al., 2022).

A cross-sectional analysis was conducted first, and the serum anti-RBC-IgG and neutralizing antibodies (Nabs) levels, as well as the frequency of MBCs and their four subpopulations were evaluated for all the participants 21-105 days after the full course of vaccination. The dynamic changes in the serum antibody titer and the frequency of MBCs were studied during the follow-up. Finally, we collected the antibody titer of those who had received a booster vaccine (see flowchart in Figure 1).

Adverse events (Aes) at 7 days and 30 days were collected using a questionnaire in the outpatient center or by phone call. The classification of Aes was based on the scale issued by the National Medical Products Administration of China (version 2019). Chemotherapy, radiotherapy, molecularly targeted therapy, or immunotherapy within 6 months after or before vaccination was considered active anticancer therapy. Other clinical data were collected from the electronic medical database.

This study was approved by the Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University and conformed with the ethical guidelines of the Declaration of Helsinki. Written informed consent was obtained from all participants.

SARS-CoV-2 antibody test

Plasma samples were collected for the detection of IgG antibody against the RBD of SARS-CoV-2 spike protein (anti-RBD-IgG) and NAb using capture chemiluminescence immunoassays performed using MAGLUMI™ X8 (Snibe, Shenzhen, China) according to the manufacturer’s instructions. According to the kit, anti-S-RBD-IgG tests have 100% sensitivity and 99.6% specificity, while NAb tests have 100% sensitivity and 100% specificity for the diagnosis of COVID-19. The cutoff value for NAb was 0.15 µg/ml, while the cut-off value for anti-RBD-IgG was 1.0 AU/ml.

SARS-CoV-2-specific memory B-cell responses

Biotinylated SARS-CoV-2 spike RBD protein (Sino Biological, 40592-V08H2-B) was mixed with streptavidin BV421 (Biolegend,
405225) at a 4:1 molar ratio for 1 hour at 4°C to generate the antigen probe. According to the manufacturer's instructions, peripheral blood mononuclear cells (PBMCs) were extracted from heparinized whole blood by density gradient centrifugation with Histopaque (Sigma–Aldrich, 10771). After rinsing with FACS buffer (PBS+2% FBS), PBMCs were stained at 4°C for 30 minutes with an antigen probe (1:33.3), and the subsequent conjugated antibodies, namely anti-human CD3 (300430, Biolegend, 1:50), anti-human CD19 (302212, Biolegend, 1:50), anti-human CD21 (354918, Biolegend, 1:50), and anti-human CD27 (356406, Biolegend, 1:50). FACS cells were resuspended in 200 μL of FACS buffer after staining. The samples were subjected to flow cytometric evaluation (Beckman Coulter, CytoFLEX) and FlowJo analysis (Treestar, 10.0.7r2).

Statistical analysis

The Chi-square and Fisher's exact test were used to compare categorical variables. The Mann–Whitney U test and Kruskal–Wallis test were used to compare continuous variables. The Geom-sminow [ggplot2 package] of a single-term linear model was used to present changes in antibody titers and frequency of MBCs over time. Using simple and multivariate regression analysis, clinical parameters associated with antibody titers were identified. A P-value less than 0.05 was considered statistically significant. Statistics were analyzed using SPSS (IBM, version 24.0.0), GraphPad Prism (GraphPad Software Inc, 9.2.0) and R software (version 4.0.1) were used to create graphs.

Results

Characteristics of the enrolled participants

In total, 274 participants were enrolled in this study from October 2021 to January 2022, of which 157 participants were included in the GI cancer group, and 117 were included in the healthy control group. Of the 274 participants, 184 were male, and 90 were female. The median age was 47 (interquartile range [IQR]: 32-79 years) for the cancer patients and 53 (IQR: 44-61 years) for the healthy individuals. The median number of days post-vaccination was 47 days (IQR: 32-79 days) for the cancer patients and 52 days (IQR: 34-75 days) for the healthy participants (Table 1). Of 157 cancer patients, 78 (49.6%) had liver cancer, 64 (40.8%) had colorectal cancer, and 15 (9.6%) had gastric cancer. A total of 107 patients received active anticancer therapies, 28 had a history of anticancer therapy, and 22 had never received anticancer therapy (most of them had poor general conditions). The chemother-
apy regimens are shown in Supplementary Table 1. Other clinical characteristics are shown in Table 1, and they did not differ between the two groups.

Safety of the inactivated SARS-COV-2 vaccines

We did not find any severe AEs during the follow-up period. Pain at the injection site was the most common local nonserious AE (19.75% in the cancer group vs 20.52% in the healthy group, \( P = 0.875 \)). Fatigue and headache were the most commonly occurring systemic AEs (Table 2). The incidence of these AEs did not differ between the cancer group and healthy controls (Table 2). After 30 days of observation, no new AEs occurred in either group (Supplementary Table 2).

Antibody responses to inactivated SARS-COV-2 vaccines

The serum anti-RBD-IgG titers were significantly lower in the cancer patients compared with healthy controls (2.18 [IQR: 0.67-5.05] vs 4.36 [1.31-9.64], \( P = 0.004 \)). The seroprevalence of anti-RBD-IgG was also lower in cancer patients (70.7% vs 80.2%, \( P = 0.047 \)) (Figure 2) in addition to the NAbs titers and the seroprevalence of NAbs (0.19 [0.13-0.05] vs 0.31 [0.15-0.54], \( P = 0.001 \); 63.7% VS 75.2%, \( P = 0.042 \)) (Figure 2). In subgroup analysis, we found that patients aged \( >65 \) years, with comorbidities, higher ASA scores, diagnosed with colorectal cancer, or recipients of active anticancer therapy (especially chemotherapy) had significantly lower antibody titers (Figure 3-6, Supplementary Figures 1, 2). Next, we conducted linear regressions to identify risk factors for a lower anti-RBD-IgG titer. Both simple and multiple linear regression found that age \( >65 \) years, higher ASA scores, and administration of active chemotherapy were risk factors for a lower antibody titer (Table 3). Similar results were found regarding the NAbs (Supplementary Table 3). During the follow-up, no participant in this study was infected with COVID-19.

Memory B-cell responses to inactivated SARS-COV-2 vaccines

MBCs are considered to play an essential role in durable humoral immunity (Ao et al., 2022), and we next evaluated the frequency of RBD-specific MBCs in each group. The gating strategy and representative results are shown in Supplementary Figure 3. To our surprise, we did not find a statistically significant difference in the total frequency of RBD+ MBCs between the two groups (Figure 7). The MBCs had four subpopulations, namely resting MBCs (rMBCs), intermediate MBCs (intMBCs), activated MBCs...
of cancer patients (16.98% vs 34.13%, \( P = 0.023 \); 17.45% vs 38.11%, \( P = 0.002 \)), while the frequencies of intMBCs and atyMBCs were higher in cancer patients (40.06% vs 19.87%, \( P = 0.010 \); 25.47% vs 16.61%, \( P = 0.025 \)) (Figure 7). In the subgroup analysis, we found that participants of older age with higher ASA scores and those receiving active anti-cancer therapy had a significantly lower frequency of actMBCs and a higher frequency of intMBCs (Figure 3-6).

**Follow-up and booster vaccine**

Sixty-nine participants completed the follow-up in this study. Although it is far from satisfactory, we still present the results here. Our results showed that the anti-RBD-IgG and NAb titers decreased significantly over time in both cancer patients and healthy individuals (Figure 8). However, if a booster vaccine was given, most participants experienced a sharp increase in antibody titers (Figure 8). We also detected changes in the frequency of MBCs, and found that the frequency of both the total and subpopulations

**Table 3**

Simple and multiple regression analyses to identify risk factors to lower anti-RBD titers in GI cancer patients.

| Variables                  | Simple linear regression | P-value | Multiple linear regression | P-value |
|----------------------------|--------------------------|---------|---------------------------|---------|
| Age (years)                | -0.016 (-0.019, -0.008)  | 0.018   | -0.017 (-0.121, -0.011)   | 0.018   |
| Gender (female)            | -0.677 (-0.990, 1.105)   | 0.315   |                          |         |
| Comorbidity(ies) (no)      | -0.016 (-0.022, 0.002)   | 0.115   |                          |         |
| TNM (TNM 4)                | 0.236 (0.363, 2.249)      | 0.178   |                          |         |
| ASA (ASA 3)                | 1.226 (1.533, 2.249)      | 0.035   | 1.207 (1.503, 2.279)      | 0.033   |
| Active treatment (no)      | 0.277 (0.363, 2.249)      | 0.052   |                          |         |
| Active chemotherapy (no)   | -0.926 (-1.021, -0.119)  | 0.000   | -0.829 (-1.001, -0.109)   | 0.000   |

CI = Confidence interval; GI = gastrointestinal; RBD = receptor binding domain
of MBCs remained relatively stable in both cancer and healthy individuals (Figure 9).

Discussion

We present the results of a prospective observational study investigating the safety and immunogenicity of inactivated SARS-CoV-2 vaccines in patients with GI tumors and healthy controls. We also evaluated the RBD-specific MBC responses in these people.

Our results were consistent with previous studies (Jara et al., 2022; Joudi et al., 2022; Kang et al., 2022) and showed that inactivated vaccines were safe and well tolerated in GI cancer patients. The most common adverse effect was local pain. Thromboembolic events, myocardial infarction, convulsion, erythema multiforme, and Stevens-Johnson syndrome, which were reported in previous studies, did not occur in this study (Hippisley-Cox et al., 2021; Jabagi et al., 2022; Oosting et al., 2021; Peeters et al., 2021; See et al., 2022). It is worth emphasizing that although 107 patients received active anticancer therapies (chemotherapy, molecular-targeted therapy, and immunotherapy), no serious adverse effects were observed, which further demonstrated the safety of inactivated vaccines.

Consistent with previous studies (Amatu et al., 2022; Goshen-Lago et al., 2021; Ariamanesh et al., 2022), we found that cancer patients had significantly lower serum anti-RBG-IgG and NAb levels after a complete course of vaccination. The seroconversion rate was also lower for cancer patients; approximately 23.98% of cancer patients failed to develop an adequate immune response after vaccination compared to 16.24% of the healthy controls. These results suggested that cancer patients had low immunogenicity to inactivated SARS-CoV-2 vaccines.

In multiple linear regression, we found that old age, high ASA scores, and administration of active chemotherapy were risk factors for a lower antibody titer. Older patients often have a weakened immune system (Korayem et al., 2022). Their B and T cells are less responsive to outside stimuli. They are more likely to have a severe course of COVID-19 and with higher mortality rate (Bubar et al., 2021; Ramasamy et al., 2020; Shapiro et al., 2022). Previous studies have also reported that patients aged >65 years had significantly lower serum antibody titers after vaccination (Ariamanesh et al., 2022; Erdoğan et al., 2022). The ASA score is widely used to evaluate the clinical condition of a patient and to assess the
risks of receiving anesthesia. A higher ASA score indicates poorer clinical conditions and higher risks of anesthesia. Our results were similar to previous studies that reported that people with a poor ECOG PS (≤2) had a higher risk of lacking seroconversion (Amatu et al., 2022). NCCN and other oncological societies recommended that all cancer patients, especially those receiving active treatment, should be vaccinated as a priority (Addeo et al., 2021; Eyu et al., 2022; Yasin et al., 2022). Ruggeri (Ruggeri et al., 2022) reported that drugs interfering with DNA synthesis, multiple-agent chemotherapy, TKIs, and mTOR inhibitors might hamper the humoral response. Other researchers have also reported similar results (Ariamanesh et al., 2022; Erdoğan et al., 2022; Javadinia et al., 2022b). In accordance with these studies, our data showed that receiving active chemotherapy was independently associated with a significantly reduced humoral response to vaccination. As few patients had received targeted therapy and immunotherapy in this study, we did not analyze the impact of these treatments on the effectiveness of the vaccines. In summary, our data indicated that people with old age, high ASA scores, and those receiving active chemotherapy therapy may have decreased immunogenicity to inactivated COVID-19 vaccines. Regular testing of the serum anti-RBG-IgG and NAbs levels may be needed, and a booster vaccine may be required for those with negative seroconversion.

MBCs are terminally differentiated cells that result from a previous immune response due to antigen exposure (Lau et al., 2017; Sosa-Hernández et al., 2020). When a secondary infection occurs, MBCs differentiate into antibody-secreting cells (ASCs) and protect against the disease (Terreri et al., 2022; Wang et al., 2022). MBCs have four subpopulations: the actMBCs are primed to become ASCs, and their frequency has a close positive relationship with serum antibody levels. IntMBCs and atyMBCs are often derived from rMBCs, and they can either differentiate into actMBCs or remain unchanged and refractory to further activation by antigens or other stimuli (Salinas et al., 2021). The frequencies of intMBCs and atyMBCs were found to be elevated during chronic inflammation, and several studies have reported their negative relationship with the serum antibody level (Oliiverio et al., 2020b; Portugal et al., 2017; Terreri et al., 2022; Wildner et al., 2021). In this study, although no changes in the total numbers of MBCs could be seen, there was a decrease in the frequency of actMBCs and a significant increase in the frequencies of intMBCs and atyMBCs in cancer patients. Similar results were found for patients with old age, high ASA scores, and those receiving active chemotherapy. This may partially explain why cancer patients had a compromised humoral response to the inactivated COVID-19 vaccines.

During the follow-up after the full course of vaccination, the serum anti-RBG-IgG and NAbs levels decreased gradually over time. When a booster vaccine was given, the serum antibody titer increased sharply again. Our data showed that the frequency of

![Figure 8](image_url)

**Figure 8.** Antibody responses to SARS-COV-2 vaccines in GI cancer patients and healthy controls during follow-up.

The concentrations of anti-RBD-IgG (a, c) and NAbs (b, d) during follow-up. The red dots indicate samples collected before the BV, and the green dots indicate samples collected after BV (a-b). The blue dots indicate samples collected before BV, and the orange dots indicate samples collected after BV (c-d). The horizontal dotted lines represent the limit of detection.

GI = gastrointestinal; BV = booster vaccine; NAbs = neutralizing antibodies; RBD = receptor binding domain.
MBCs remained relatively stable after vaccination. However, it decreased slightly among cancer patients. The stable frequency of MBCs may be an important precondition for a functional booster vaccine.

The limitations of this study include the following: (1) Only 69 participants completed the follow-up in this study, which weakened the strength of the conclusions regarding the effectiveness of the vaccines during follow-up. (2) Only 25 participants received the booster vaccine; thus, further investigation is needed to determine the safety and immunogenicity of the booster vaccine. (3) T cells and other immune cells also contributed to the humoral response to the vaccines, and the functions of these cells should be studied in future research. Nonetheless, we believe this study provides essential information to clinicians and policymakers.

In conclusion, inactivated SARS-CoV-2 vaccines are safe and well tolerated in GI cancer patients. The antibody response is weak in cancer patients, especially for those with old age, high ASA scores, and those receiving active chemotherapy. The frequency of actMBCs decreased, while the frequencies of intMBCs and atyMBCs increased in cancer patients. During follow-up, the frequency of MBCs remained relatively stable for GI cancer patients. A booster vaccine may be effective and should be prioritized for GI cancer patients.

**Ethical approval**

This study was approved by the Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University and conformed with the ethical guidelines of the Declaration of Helsinki.

**Author contributions**

Tong Li, Rui Song, and Jingjie Wang were responsible for the draft writing and data collection and contributed equally to this study. Jianbo Zhang, Hongxing Cai, Hongmei He, Wei Hu, Dajun Yu, Chuanhu Wang, Qingbo Pan and Mingli Peng were responsible for the data collection, data analysis and follow-up of the patients. Peng Zhu and Hong Ren were responsible for the design and supervision of this study.

**Funding information**

This work is supported by the National Science and Technology Major Project of China (2017ZX10202203-007, 2018ZX10302206-003). We also acknowledge the support of the National Natural Science Foundation of China (81772198), Natural Science Founda-
tion of Chongqing, China (cstc2020cjcyj-msxm0389), KuanRen Excellent Doctor project (kryc-yq-2220; ky2019y008)

Declaration of Competing Interest
The authors have no conflicts of interest to declare.

Acknowledgments
We would like to thank Professor Jijian Wang, Yaxu Wang, Yang Li, Daihua Zhu (Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Chongqing Medical University) for helping collect the data for this study.

Supplementary materials
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jid.2022.07.050.

References
Addeo A, Shah PK, Bordry N, Hudson RD, Albright B, Di Marco M, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell 2021;39:1091–1098.e2.
Anwar A, Pani A, Patelli G, Gagliardi OM, Loparco M, Piscazzi D, et al. Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving antitumor treatment. Eur J Cancer 2022;163:16–25.
Ao L, Lu T, Cao Y, Chen Z, Wang Y, Li Z, et al. Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in people living with HIV. Emerg Microbes Infect 2022;11:1126–34.
Ariamanesh T, Li, 2022;10:e798–806.
Ariamanesh T, Thompson J, Mathews V, Morrison R, Hemmig K. Randomized controlled trials in patients with COVID-19: a systematic review and critical appraisal. Int J Infect Dis 2022;122:72–80.
Lau D, Lan LY, Andrews SF, Henry C, Rojas KT, Neu KE, et al. Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation. Sci Immunol 2017;2:eaaal153.
Lyudovyck O, Kim YJ, Qualls D, Hwee MA, Lin YH, Boutemine SR, et al. Impaired humoral immunity is associated with prolonged COVID-19 disease despite robust CD8+ T cell responses. Cancer Cell 2022;40:736–735.e5.
Mattiazzu C, Lippi G. Real-world effectiveness of COVID-19 vaccination among children in Italy. Int J Infect Dis 2022;122:70–1.
Ngaterek PB, Oyola SO, Baenpi SF, Ronoz GK, Birindwa AB, Shukuru DW, et al. Whole-genome sequencing of SARS-CoV-2 reveals diverse mutations in circulating Alpha and Delta variants during the first, second, and third waves of COVID-19 in South Kivu, the Democratic Republic of the Congo. Int J Infect Dis 2022;136:13–43.
Olivero B, Vauchela S, Mele D, Mantovani S, Cerino A, Perotti CG, et al. Expansion of atypical memory B cells is a prominent feature of COVID-19. Cell Mol Immunol 2020;17:1101–3.
Oosting SF, van der Veldt AAM, Geertsvankessel CH, Fahrmann RSN, van Binnendijk RS, Dingenans AC, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol 2022;23:1081–91.
Peeters M, Verbruggen L, Teuwen L, Vanhoutte G, Vande Kerkhove S, Peeters B, et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. J Am Soc Nephrol 2022;33:2054–63.
Portugal S, Obeng-Adjei N, Moir S, Crompton PD, Pierce SK. Atypical memory B cells in human chronic infectious diseases: an interrim report. Cell Immunol 2017;321:18–25.
Sahin A, Lesniak AM, Ewer KJ, Flaxman AL, Foleyatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a primate-boost regime in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2020;396:1979–93.
Ruggieri EM, Nelli F, Fabbrini A, Onorato A, Giannarelli D, Giron Berrios JR, et al. Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study. ESMO Open 2022;7.
Salinas AF, Mortari EP, Terriers S, Quistarelli C, Pulvirenti F, Di Cecca S, et al. SARS-CoV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best. J Clin Immunol 2021;41:1709–22.
See I, Lale A, Marquez P, Streiff MR, Wheeler AP, Tepper NK, Woo EJ, Broder KR, Edwards KM, Gallego R, Celler AL, Jackson KA, Sharma S, Talaat KR, Walter EB, Akanji IA, Ortel TL, Urrutia VC, Walker SC, Yui JC, Shimabukoro TT, Mba-Jonas A, Su JR, Shay DK. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-united states, December 2020 to August 2021. Ann Intern Med 2022;175:313–22.
Shahidinej S, Aledavood SA, Jouidi M, Molaei F, Esmaeii H, Javadinia SA. COVID-19 patients in cancer may be affected by atypical symptoms and higher mortality rate, a case-controlled study from Iran. Cancer Res. (Hoboken) 2021;4:elc1378.
Skog SJ, Sitaras I, Park J, Carli M, Li M, et al. Association of frailty, age, and biological sex with SARS-CoV-2 mRNA vaccine-induced immunity in older adults. Clin Infect Dis Forthcoming 2022:ciaa397.
Sosa-Hernández VA, Torres-Ruíz J, Cervantes-Díaz R, Romero-Ramírez S, Puezo-Franco JC, Meza-Sánchez DE, et al. B cell subsets as severity-associated signatures in COVID-19 patients. Front Immunol 2020;11.
Tajaghazadeh-Hesary F, Porouhan P, Soroush D, PeyroshShabany B, ShahidiSes, Keykhabar B, et al. COVID-19 in cancer and Non-cancer patients. Int J Cancer Manag 2021;14.
Terriers S, Miano Mortari I, Vinci MR, Russo C, Alteri C, Albano C, et al. Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. Cell Host Microbe 2022;30:400–408.e4.
Wang CY, Hwang KP, Kuo HK, Peng WJ, Shen YH, Kuo BS, et al. A multipoise SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. J Clin Invest 2022;132.
Willemsen NH, Ahmadzeh P, Schulte T, Brauneck F, Koehm M, Lüdtgemannt, et al. B cell analysis in SARS-CoV-2 versus malaria: increased frequencies of plasmablasts and atypical memory B cells in COVID-19. J Leukoc Biol 2021;97:79–90.
Yasin AI, Aydin SC, Sümül B, Koral L, Şimşek M, Geredeli C, et al. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncol 2022;18:1235–44.